Lead Product(s): ATH434
Therapeutic Area: Neurology Product Name: ATH434
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2020
Data from bioMUSE will also be used to inform patient selection in Alterity’s upcoming Phase 2 clinical trial of ATH434, its lead clinical candidate for the treatment of MSA.